Supplementary Table S3. Univariable Cox regression analyses for DFS and OS

Variable	DFS		OS	
	HR (95% CI)	p-value	HR (95% CI)	p-value
CPS (>5 vs. ≤5)	0.18 (0.04–0.78)	.022	0.17 (0.02–1.32)	.09
IC expression (1%–5% vs. <1%)	1.04 (0.39–2.77)	.944	1.44 (0.46–4.48)	.528
IC expression (>5% vs. <1%)	0.31 (0.07–1.48)	.143	0.31 (0.04–2.58)	.279
TC expression (1%–5% vs. <1%)	0.90 (0.35–2.24)	.824	2.22 (0.77–6.96)	.141
TC expression (>5% vs. <1%)	0.26 (0.00–2.02)	.249	0.75 (0.01–6.07)	.843
LVI (yes vs. no)	1.24 (0.44–3.49)	.683	0.92 (0.25–3.36)	.899
PNI (yes vs. no)	0.70 (0.25–1.96)	.495	0.81 (0.25–2.64)	.729
TNM stage (II vs. I)	1.83 (0.35–9.51)	.47	1.70 (0.19–15.32)	.638
TNM stage (III vs. I)	1.09 (0.24–5.10)	.908	0.84 (0.10–7.19)	.871
TNM stage (IV vs. I)	2.54 (0.36–18.17)	.352	3.35 (0.35–32.28)	.296
Sex (male vs. female)	0.65 (0.26–1.66)	.371	1.31 (0.40–4.27)	.649
Age (per 10-year increase)	1.02 (0.70–1.50)	.906	1.08 (0.66–1.76)	.773
Tumor location (right vs. left)	0.33 (0.07–1.51)	.152	0.43 (0.09–2.14)	.302
Tumor location (rectum vs. left)	0.64 (0.24–1.73)	.381	0.72 (0.22–2.37)	.59
Differentiation (poor vs. well/moderate)	0.34 (0.00–2.48)	.366	1.91 (0.24–15.37)	.543
Metastasis (M1) (yes vs. no)	2.02 (0.78–5.23)	.145	0.80 (0.27–2.41)	.695

HRs with 95% CIs were estimated using univariable Cox proportional hazards regression. All p-values are two-sided. CPS was analyzed as >5 versus ≤5; IC and TC were analyzed using <1% as the reference category. Tumor necrosis and tumor size were not entered because of sparse events and unstable estimates.

DFS, disease-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; CPS, combined positive score; IC, immune-cell PD-L1; TC, tumor-cell PD-L1; LVI, lymphovascular invasion; PNI, perineural invasion.